Citations

Clear

4610 citation(s) found for "Lu, Brian".

Experts Achieve Consensus on a Majority of Statements Regarding Ethics, Transparency, Regulation, and Best Practices for the Use of Orthobiologics
Gilat, Ron , Muth, Sarah A. , Hurley, Eoghan T. , Yazdi, Allen A. , Franzia, Chloe H, Shapiro, Shane A. , Cole, Brian J. , Shapiro, Shane , Franzia, Chloe H., Rodeo, Scott A. , Frank, Rachel M , Kon, Elizaveta

Mayo Clinic

Arthroscopy | February 10, 2025 | Volume: 41 | Issue: 9 | Pages: 3611-3621

10.1016/j.arthro.2025.01.062 | PMID 39938667 Get It

Purpose To establish consensus statements via a modified Delphi process about ethics, transparency, regulation, and best practices for the use of orthobiologics in clinical practice for musculoskeletal pathology. Methods A consensus process on the regulation of orthobiologics at the provider level was conducted using a modified Delphi technique. Twenty orthopaedic surgeons, sports medicine physicians, or basic scientists participated. Each participant was a Biologic Association member organization representative and asked to participate because of their active interest in the field of orthobiologics. Levels of consensus were delineated according to the number of votes for each statement: no consensus, <80%; consensus, 80% to 89%; strong consensus, 90% to 99%; unanimous, 100%. Results The 26 consensus statements on orthobiologics resulted in 14 achieving unanimous consensus, 8 achieving strong consensus, 3 achieving consensus, and 1 did not achieve consensus. Overall, 85% of the statements reached either a unanimous or strong consensus. Of the statements regarding communication and transparency, 9 reached unanimous consensus, including information to convey and helpful tools to describe current orthobiologics, persistent misinformation, use of the word “stem cells,” “off‐label” use, and problems with the present regulatory environment. Five statements discussing the regulation of novel orthobiologics achieved unanimous consensus. These statements highlighted research regulation, safety, and suggested improvements to regulatory issues. The statement that did not achieve any consensus was on the regulatory processes that should be in place by an institution providing novel orthobiologic treatments. No statement reached a unanimous agreement on cost or ethical considerations. Conclusions This study successfully identified key consensus statements emphasizing the importance of ethics, transparency, and regulation in the use of orthobiologics, with 85% of statements reaching unanimous or strong consensus. These findings underscore the need for standardized communication, improved regulatory frameworks, and enhanced safety measures while highlighting persistent challenges in addressing cost and ethical considerations. Level of Evidence Level V, expert opinion.
Assessing the Prognostic Value of Upfront Neck Disease in Olfactory Neuroblastoma: A Multicenter, Matched Cohort Study
Fung, Nicholas , Patel, Shivam , Champagne, Pierre‐Olivier , Fernandez‐Miranda, Juan C. , Gardner, Paul , Patel, Chirag , Celda, María Peris, Sanusi, Olabisi , Snyderman, Carl, Thorp, Brian D. , Zenonos, Georgios A. , Zwagerman, Nathan T. , Fung, Nicholas, Almeida, João Paulo , Hwang, Peter H. , Nayak, Jayakar V. , Patel, Zara M. , Pinheiro‐Neto, Carlos , Gompel, Jamie J. Van , Geltzeiler, Mathew , Choby, Garret , Wang, Eric W

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803566 Get It

Differences in Disease Presentation and Rates of Positive Genetic Testing between Patients Diagnosed with NF2-Related Schwannomatosis Before and After 30 Years of Age
Carlson, Matthew L. , Neff, Brian, Driscoll, Colin L. W., Babovic‐Vuksanovic, Dusica , Dornhoffer, James R. , Olson, Brennan , Neff, Brian A., Schimmenti, Lisa A.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803300 Get It

The Use of Induction Chemotherapy in Olfactory Neuroblastoma: A Multi-institutional Series
Tang, Anthony , Champagne, Pierre‐Olivier , Fernandez‐Miranda, Juan C. , Gardner, Paul A. , Peris-Celda, Maria, Sanusi, Olabisi , Thorp, Brian D. , Zenonos, Georgios A. , Zwagerman, Nathan T. , Adida, Samuel , Almeida, João Paulo , Hwang, Peter H. , Nayak, Jayakar V. , Patel, Chirag, Patel, Zara M. , Peris‐Celda, Maria , Pinheiro‐Neto, Carlos , Snyderman, Carl H , Gompel, Jamie J. Van , Wang, Eric W , Geltzeiler, Mathew , Choby, Garret

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803170 Get It

Proton Beam Radiotherapy versus Intensity-Modulated Radiotherapy in Olfactory Neuroblastoma: A Multi-institutional Propensity-Matched Study
Tang, Anthony , Champagne, Pierre‐Olivier , Fernandez‐Miranda, Juan C. , Gardner, Paul , Nayak, Jayakar, Peris-Celda, Maria, Sanusi, Olabisi , Snyderman, Carl, Thorp, Brian D. , Zenonos, Georgios A. , Zwagerman, Nathan T. , Donohue, Jack K. , Adida, Samuel , Almeida, João Paulo , Hwang, Peter H. , Patel, Chirag, Patel, Zara M. , Peris‐Celda, Maria , Pinheiro‐Neto, Carlos , Gompel, Jamie J. Van , Wang, Eric W , Geltzeiler, Mathew , Choby, Garret

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803169 Get It

Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐ GemOx : A Multicenter Cohort Study
Yamshon, Samuel , Koff, Jean L. , Larson, Melissa C. , Kahl, Brad S. , Casulo, Carla , Lossos, Izidore S. , Haddadi, Sara , Stanchina, Michele , Chihara, Dai , Ayers, Amy , Khurana, Arushi , Nowakowski, Grzegorz S. , Reicks, Tanner W., Cohen, Jonathon B. , Martin, Peter , Li, Jia , Shewade, Ashwini, Batlevi, Connie Lee , Lo‐Rossi, Andrea, Fox, David , Masaquel, Anthony, Mun, Yong, Flowers, Christopher R. , Habermann, Thomas , Wang, Yucai , Khurana, Arushi , Nowakowski, Grzegorz S , Farooq, Umar , Link, Brian K , Cohen, Jonathon B , Li, Jia , Shewade, Ashwini , Batlevi, Connie L , Lo-Rossi, Andrea , Fox, David , Masaquel, Anthony , Cerhan, James R , Maurer, Matthew , Kahl, Brad S , Koff, Jean L , Chihara, Dai , Casulo, Carla , Larson, Melissa C , Habermann, Thomas M. , Wang, Yucai , Link, Brian K. , Cerhan, James R. , Maurer, Matthew J. , Nastoupil, Loretta J.

Mayo Clinic

American Journal of Hematology | February 7, 2025 | Volume: 100 | Issue: 4 | Pages: 606-615

10.1002/ajh.27630 | PMID 39918101 Get It

ABSTRACT Rituximab, gemcitabine, and oxaliplatin (R‐GemOx) is a commonly used chemoimmunotherapy regimen for relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL), but there are limited real‐world data. In a multicenter retrospective study from a cohort of eight US academic centers (LEO CReWE), we evaluated 183 patients with R/R DLBCL and high‐grade B cell lymphoma treated with R‐GemOx, including subgroups treated without intent for consolidation with autologous stem cell transplant (ASCT) or chimeric antigen receptor (CAR) T cell therapy ( n = 100), those utilizing R‐GemOx as a bridge to ASCT or CAR T ( n = 83), and those aged 70 and older ( n = 71). Overall response rates (ORRs) for all patients treated with R‐GemOx were 45% with a complete response (CR) rate of 29%. The median event‐free survival (EFS) was 2.3 months, and the median overall survival (OS) was 13.5 months. Patients receiving R‐GemOx without intent for ASCT or CAR T had ORR and CR rates of 33% and 18%, respectively, with median EFS and OS of 2.0 and 9.5 months, respectively. Patients receiving R‐GemOx as a bridge to ASCT or CAR T had ORR and CR rates of 57% and 36%, respectively, with median EFS and OS of 3.5 and 17.4 months, respectively. Patients receiving R‐GemOx aged 70 and older had ORR and CR rates of 53% and 33%, respectively, with median EFS and OS of 2.2 and 13.9 months, respectively. These data provide a benchmark for R‐GemOx in the rapidly evolving landscape of R/R DLBCL therapies.
Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion
Goyal, Mayank , Möhlenbruch, Markus , Nimjee, Shahid M. , Buck, Brian , Kennedy, James , Zhang, Liqun , Hametner, Christian , Nardai, Sándor , Zafar, Atif , Diprose, William K. , Vatanpour, Shabnam , Stebner, Alexander, Bosshart, Salome , Uchida, Kazutaka , Ryckborst, Karla J., Fahed, Robert, Hu, Sherry , Zaidi, Syed , Lee, Vivien , Teal, Rachel, Trivedi, Anurag , Ogungbemi, Ayokunle, Orosz, Péter , Abdalkader, Mohamad , Taschner, Christian , Tarpley, Jason , Poli, Sven , Sahlas, Demetrios J. , Burns, Paul , Marigold, Richard , Amole, Adewumi, Field, Thalia S. , Settecase, Fabio , Lenzsér, Gábor, Asdaghi, Negar , Lobotesis, Kyriakos , Siddiqui, Adnan H. , Berrouschot, J., Ebersole, Koji , Schneider, Hauke , Mandzia, Jennifer, Klostranec, Jesse , Jadun, Changez, Patankar, Tufail , Sauvageau, Eric , Lenthall, Robert , Peeling, Lissa, Budzik, Ronald F. , Lee, Seon-Kyu, Perry, Richard , Hlaing, Thant , Singh, Paul, Hill, Michael D. , Vakharia, Kunal , Harston, George , Möhlenbruch, Markus A , Nimjee, Shahid M , Buck, Brian H , Kennedy, James , Zhang, Liqun , Hametner, Christian , Diprose, William , Vatanpour, Shabnam , Stebner, Alexander , Bosshart, Salome , Singh, Nishita , Hu, Sherry X , Vollherbst, Dominik F , Lee, Vivien H , Rempel, Jeremy L , Teal, Rachel , Trivedi, Anurag , Bode, Felix J , Abdalkader, Mohamad , Poli, Sven , Singh, Ravinder-Jeet , Lopez, George , Schaafsma, Joanna D , Marigold, Richard , Field, Thalia S , Settecase, Fabio , Ortega-Gutierrez, Santiago , Mokin, Maxim , Ebersole, Koji , Schneider, Hauke , Yoo, Albert J , Klostranec, Jesse , Lenthall, Robert , Huynh, Thien , Budzik, Ronald , Levitt, Michael R , Jahromi, Babak S , Hill, Michael D , Siddiqui, Adnan H , Ospel, Johanna M. , Ganesh, Aravind , Dowlatshahi, Dar , Volders, David , Jumaa, Mouhammad , Booth, Thomas Calvert , Shankar, Jai , Dorn, Franziska , Sebastian, Ivy Anne , Fahed, Robert , Lynch, Jeremy , Bode, Felix J. , Pham, Mirko , Leacy, Reade De , Chen, Michael , Reich, Arno , Swartz, Richard H. , Yoo, Albert J. , Huynh, Thien , Makalanda, Levansri , Levitt, Michael R. , Jahromi, Babak S. , Demchuk, Andrew M.

Mayo Clinic

New England Journal of Medicine | February 5, 2025 | Volume: 392 | Issue: 14 | Pages: 1385-1395

10.1056/nejmoa2411668 | PMID 39908448 Get It

The landscape of autosomal-dominant Alzheimer’s disease: global distribution and age of onset
Liu, Haiyan , Marsh, Thomas W. , Shi, Xinyu , Bowling, Kevin M. , Ziegemeier, Ellen , Wang, Guoqiao , Cao, Yuchen , Aristel, Alisha, Li, Jessie, Dickson, Alexa , Perrin, Richard J. , Goate, Alison , Fernández, María Victoria , Day, Gregory S. , Doering, Michelle , Daniels, Alisha , Hassenstab, Jason , Supnet, Charlene , Xiong, Chengjie , Berman, Sarah , Ryan, Natalie S. , Huey, Edward D. , Noble, James M. , Roh, Jee Hoon , Laske, Christoph , Sánchez‐Valle, Raquel , Méndez, Patricio Chrem, Chhatwal, Jasmeer P. , Farlow, Martin R. , Xiong, Chengjie , Gordon, Brian A , Ibanez, Laura , Vöglein, Jonathan , Roh, Jee Hoon , Ikeuchi, T , Sánchez-Valle, Raquel , Chhatwal, Jasmeer , Xiong, Chengjie , Rosa-Neto, Pedro , Schofield, Peter R , Bateman, Randall J , Cruchaga, Carlos , Day, Gregory S , Hassenstab, Jason , Fernandez, Maria , Goate, Alison M , Supnet-Bell, Charlene , Berman, Sarah , Noble, James M , Renton, Alan , Gordon, Brian A. , Benzinger, Tammie L.S. , Allegri, Ricardo , Fox, Nick C. , Vöglein, Jonathan , Jucker, Mathias , Ikeuchi, Takeshi , Schofield, Peter R. , Lee, Jae‐Hong , Levey, Allan I. , Lopera, Francisco Javier , Martins, Ralph N. , Niimi, Yoshiki , Bateman, Randall J. , Karch, Celeste M. , McDade, Eric , Llibre‐Guerra, Jorge J.

Mayo Clinic

Brain | February 4, 2025 | Volume: 148 | Issue: 7 | Pages: 2429-2440

10.1093/brain/awaf038 | PMID 39903689 Get It

Abstract We present a comprehensive global analysis of genetic variants associated with autosomal-dominant Alzheimer’s disease (ADAD). A total of 550 variants in the APP, PSEN1 and PSEN2 genes were identified, of which 279 were classified as pathogenic or likely pathogenic based on American College of Medical Genetics and Genomics and the Association for Molecular Pathology criteria, utilizing data from the Dominantly Inherited Alzheimer Network (DIAN), literature and public databases. Symptomatic age at onset (AAO) data were estimated for 227 of these variants, allowing detailed characterization of their frequency, pathogenicity and AAO. Importantly, 226 variants met eligibility criteria for inclusion in disease-modifying clinical trials. Furthermore, we demonstrated the predictive value of mean variant AAO and parental AAO in predicting symptomatic AAO, validated against converters who became symptomatic during follow-up in the DIAN Observational Study. This dataset provides critical insights into the global landscape of ADAD and reveals the genetic and AAO heterogeneity of ADAD variants while refining variant trial eligibility criteria.
1727: VETTING THE DATA: SYSTEMATIC REVIEW OF VISCOELASTIC TESTING IN NEUROLOGIC EMERGENCIES
Vollmer, Nicholas , Gerberi, Dana , Brown, Caitlin S. , Gilbert, Brian W. , Rech, Megan A.

Mayo Clinic

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001105572.08881.99 Get It

Rates of Minimally Invasive Surgery After Introduction of Robotic-Assisted Surgery for Common General Surgery Operations
Wall‐Wieler, Elizabeth , Johnson, Shaneeta, Culbertson, Richard, Fong, Zhi Ven , Johnson, Shaneeta M. , Mitzman, Brian

Mayo Clinic

Annals of Surgery Open | January 31, 2025 | Volume: 6 | Issue: 1 | Pages: e546

10.1097/as9.0000000000000546 | PMID 40134491 Get It

Importance: Many patients who would benefit from minimally invasive surgery (MIS) have open surgery; robotic-assisted surgery (RAS) addresses some of the limitations of laparoscopic surgery and could increase rates of MIS across different patient populations. Objective: To determine whether the introduction of RAS increases MIS rates and whether increases are seen across different patient populations undergoing common general surgery procedures. Design: A retrospective cohort study was performed to compare rates of MIS in the year before and after the index date for hospitals that did and did not introduce RAS. Generalized estimating equation regression models were used to compare rates in MIS over time. Setting: PINC AI Healthcare Database, an all-payor discharge database of hospitals in the United States. Participants: Hospitals that performed cholecystectomy, inguinal hernia repair, ventral hernia repair, and colorectal resection from 2016 to 2022. Exposure: RAS hospitals performing at least 1 common general surgery procedure using RAS. Main Outcome and Measure: The primary analysis examined rates of MIS, defined as the rate of common general surgeries that were minimally invasive (laparoscopic or RAS) in a hospital. The secondary analysis examined MIS rates for common general surgeries, across age, sex, race, ethnicity, and payor. Results: Of 408 hospitals included in the study, 153 (38%) introduced RAS for common general surgeries. The relative MIS rate for hospitals that introduced RAS compared with hospitals that did not went from 1.08 (95% confidence interval [CI], 1.02–1.14; P < 0.01) before the index date to 1.15 (95% CI, 1.09–1.22; P < 0.01) after the index date (P interaction < 0.01), indicating a larger increase in MIS rates among hospitals introducing RAS. MIS rates increased significantly more in hospitals that introduced RAS across patient age, sex, ethnicity, race, and payor compared with hospitals that did not introduce RAS. Conclusions and Relevance: Hospitals that introduced RAS for common general surgery procedures were associated with an increase in MIS rates across different patient populations compared with hospitals that did not introduce RAS.